Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 5 | Journal of Ovarian Research

Fig. 5

From: Narrowing the field: cancer-specific promoters for mitochondrially-targeted p53-BH3 fusion gene therapy in ovarian cancer

Fig. 5

Cancer Specificity of hTERT Promoters. Every promoter indicates significantly lower expression in the normal cells versus every cancer cell line, while the untreated and CMV control columns indicate no significant different between normal (BJ) cells and any of the ovarian cancer cells. For each column n = 3, and statistical analysis was performed using 2-way ANOVA and Bonferroni’s post-test. Each * corresponds to a P value < 0.001 when the respective ovarian cancer cell column is compared to the normal cell (BJ) column in the same category with Bonferroni’s post-test

Back to article page